JP2013510885A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510885A5
JP2013510885A5 JP2012539065A JP2012539065A JP2013510885A5 JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5 JP 2012539065 A JP2012539065 A JP 2012539065A JP 2012539065 A JP2012539065 A JP 2012539065A JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5
Authority
JP
Japan
Prior art keywords
formula
composition
compound
nhch
optical isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539065A
Other languages
English (en)
Japanese (ja)
Other versions
JP5650233B2 (ja
JP2013510885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056760 external-priority patent/WO2011060392A1/en
Publication of JP2013510885A publication Critical patent/JP2013510885A/ja
Publication of JP2013510885A5 publication Critical patent/JP2013510885A5/ja
Application granted granted Critical
Publication of JP5650233B2 publication Critical patent/JP5650233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539065A 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 Active JP5650233B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US61/261,301 2009-11-13
US26247409P 2009-11-18 2009-11-18
US61/262,474 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013235966A Division JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Division JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Publications (3)

Publication Number Publication Date
JP2013510885A JP2013510885A (ja) 2013-03-28
JP2013510885A5 true JP2013510885A5 (enExample) 2014-01-09
JP5650233B2 JP5650233B2 (ja) 2015-01-07

Family

ID=43992106

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012539065A Active JP5650233B2 (ja) 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Country Status (32)

Country Link
US (4) US8362048B2 (enExample)
EP (3) EP2498610B2 (enExample)
JP (3) JP5650233B2 (enExample)
KR (2) KR101721716B1 (enExample)
CN (2) CN102762100B (enExample)
AU (1) AU2010319983B2 (enExample)
BR (2) BR112012011427B8 (enExample)
CA (2) CA2986521C (enExample)
CY (3) CY1120338T1 (enExample)
DK (2) DK2498610T4 (enExample)
EA (2) EA035768B1 (enExample)
ES (2) ES2673160T5 (enExample)
FI (2) FIC20200044I1 (enExample)
FR (1) FR20C1059I2 (enExample)
HR (2) HRP20180874T4 (enExample)
HU (3) HUE054000T2 (enExample)
IL (2) IL219691B (enExample)
LT (3) LT2498610T (enExample)
LU (1) LUC00184I2 (enExample)
MX (1) MX2012005560A (enExample)
MY (2) MY161854A (enExample)
NO (2) NO2498610T3 (enExample)
NZ (1) NZ599915A (enExample)
PH (2) PH12012500939A1 (enExample)
PL (2) PL3406142T3 (enExample)
PT (2) PT2498610T (enExample)
RS (2) RS57253B2 (enExample)
SG (1) SG10201407357PA (enExample)
SI (2) SI3406142T1 (enExample)
SM (2) SMT201800288T1 (enExample)
TR (1) TR201807912T4 (enExample)
WO (1) WO2011060392A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005560A (es) 2009-11-13 2012-10-05 Receptos Inc Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
ES2665461T3 (es) * 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
MX355261B (es) * 2012-06-21 2018-04-12 Eisai R&D Man Co Ltd Derivado de indanosulfamida novedoso.
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
EP3280703A1 (en) 2015-04-06 2018-02-14 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
EP4566676A3 (en) * 2016-06-14 2025-11-05 Receptos LLC Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
ES2877686T3 (es) * 2016-07-22 2021-11-17 Shijiazhuang Sagacity New Drug Dev Co Ltd Agonista S1P1 y aplicación del mismo
CN109563059A (zh) * 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
WO2018050091A1 (zh) 2016-09-14 2018-03-22 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
CN108137516A (zh) * 2016-09-14 2018-06-08 杭州领业医药科技有限公司 奥扎莫德的晶型、其制备方法及药物组合物
KR102408814B1 (ko) * 2016-09-29 2022-06-14 리셉토스 엘엘씨 루푸스를 치료하기 위한 화합물 및 방법
CN110325517B (zh) * 2017-02-28 2021-03-02 南京明德新药研发有限公司 螺环类化合物及其应用
WO2018184185A1 (zh) * 2017-04-07 2018-10-11 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
EP3621610A1 (en) 2017-05-08 2020-03-18 Celgene International II Sàrl Sphingosine 1 phosphate receptor agonists for neuroprotection
US12459907B2 (en) 2017-05-22 2025-11-04 Egis Gyogyszergyar Zrt. Process for the production of ozanimod
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
EP3677575A4 (en) * 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
KR20200128386A (ko) * 2018-01-18 2020-11-12 스자좡 서개시티 뉴 드러그 디벨롭먼트 컴퍼니, 엘티디. 트리사이클릭 화합물의 결정형 및 염 형태, 및 이의 제조방법
KR20200132858A (ko) 2018-03-20 2020-11-25 에자이 알앤드디 매니지먼트 가부시키가이샤 간질 치료제
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
WO2020005313A1 (en) 2018-06-25 2020-01-02 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
EP3849965A1 (en) 2018-09-12 2021-07-21 Pharmazell GmbH A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
ES2962211T3 (es) * 2018-12-07 2024-03-18 Synthon Bv Proceso mejorado para preparar ozanimod
KR20210150371A (ko) * 2019-03-29 2021-12-10 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
WO2020205478A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
JP2022528001A (ja) * 2019-03-29 2022-06-07 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１リン酸受容体調節因子
KR20220007065A (ko) * 2019-04-26 2022-01-18 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절인자
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
US12404256B2 (en) 2019-07-16 2025-09-02 Synthon B.V. Process for preparing ozanimod
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
AU2021205465A1 (en) * 2020-01-06 2022-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11760751B2 (en) 2020-03-04 2023-09-19 Helioeast Science & Technology Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
WO2021175225A1 (zh) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 三环类化合物及其应用
EP4121025A4 (en) * 2020-03-17 2024-03-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
EP4126829B1 (en) 2020-03-27 2026-02-18 Receptos LLC Sphingosine 1 phosphate receptor modulators
KR20220158745A (ko) * 2020-03-27 2022-12-01 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
US12398112B2 (en) 2020-04-02 2025-08-26 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
WO2022213935A1 (zh) * 2021-04-09 2022-10-13 南昌弘益药业有限公司 噁二唑取代的螺环类化合物及其应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
EP4720047A1 (en) 2023-05-31 2026-04-08 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
EP0583346A1 (en) 1991-04-12 1994-02-23 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
PT1057827E (pt) * 1998-01-23 2003-11-28 Sankyo Co Derivados da espiropiperidina
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
DE60335827D1 (de) 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
HUE047569T2 (hu) 2003-04-11 2020-04-28 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1851188A1 (en) 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
RU2420279C3 (ru) † 2005-08-03 2017-03-14 Новартис Аг Применение ингибиторов hdac для лечения миеломы
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
CA2634488C (en) 2005-12-21 2016-10-04 Joseph Gabriele Catecholamine regulated protein
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
ES2393412T3 (es) * 2006-09-21 2012-12-21 Actelion Pharmaceuticals Ltd. Derivados de fenilo y su uso como inmunomoduladores
CA2669104A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
EP2109364A4 (en) 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008106204A1 (en) 2007-02-28 2008-09-04 Rib-X-Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009131090A1 (ja) 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
EP3782991A1 (en) * 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
CN102066752B (zh) * 2008-06-13 2014-02-19 (学)斗源学院 具有回转阀的往复式压缩机
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
ES2665461T3 (es) 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
MX2012005560A (es) 2009-11-13 2012-10-05 Receptos Inc Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
PH12012500940B1 (en) 2009-11-13 2018-09-26 Receptos Llc Selective heterocyclic sphingosine 1 phosphate receptor modulators
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Similar Documents

Publication Publication Date Title
JP2013510885A5 (enExample)
JP2015505296A5 (enExample)
JP2014506907A5 (enExample)
JP2016534063A5 (enExample)
SI2498610T1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
JP2011527691A5 (enExample)
JP2013032389A5 (enExample)
JP2013537203A5 (enExample)
JP2012092103A5 (enExample)
JP2009242409A5 (enExample)
JP2012532883A5 (enExample)
JP2009535358A5 (enExample)
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
JP2018537535A5 (enExample)
JP2020507589A5 (enExample)
JP2007302689A5 (enExample)
JP2013542992A5 (enExample)
JP2015535847A5 (enExample)
JP2010529994A5 (enExample)
JP2009543795A5 (enExample)
JP2013533253A5 (enExample)
JP2019516739A5 (enExample)
JP2013514980A5 (enExample)
JP2020505354A5 (enExample)
JP2015509075A5 (enExample)